

# Jeffrey Schlom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1404807/publications.pdf>

Version: 2024-02-01

350  
papers

23,917  
citations

9254

74  
h-index

11601

135  
g-index

354  
all docs

354  
docs citations

354  
times ranked

18311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. <i>Journal of Experimental Medicine</i> , 2006, 203, 1259-1271.	4.2	1,389
2	Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1099-1105.	0.8	900
3	Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. <i>Blood</i> , 2005, 105, 2862-2868.	0.6	810
4	Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors. <i>Hybridoma</i> , 1984, 3, 223-232.	0.9	502
5	Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes. <i>Cancer Research</i> , 2004, 64, 7985-7994.	0.4	489
6	External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing. <i>Cancer Research</i> , 2004, 64, 4328-4337.	0.4	410
7	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	1.6	391
8	Cancer Vaccines: Moving Beyond Current Paradigms. <i>Clinical Cancer Research</i> , 2007, 13, 3776-3782.	3.2	367
9	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3353-3362.	3.2	357
10	Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses. <i>Journal of Clinical Oncology</i> , 2000, 18, 3964-3973.	0.8	337
11	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 501-508.	5.1	333
12	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF $\beta$ 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304
13	Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. <i>Experimental Biology and Medicine</i> , 2011, 236, 567-579.	1.1	298
14	Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 720-731.	0.8	290
15	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1260-1269.	3.2	286
16	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 663-674.	2.0	279
17	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
18	Therapeutic Cancer Vaccines: Current Status and Moving Forward. <i>Journal of the National Cancer Institute</i> , 2012, 104, 599-613.	3.0	239

#	ARTICLE	IF	CITATIONS
19	The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 533-544.	3.9	238
20	In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen. <i>Journal of the National Cancer Institute</i> , 1997, 89, 293-300.	3.0	228
21	Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2122-2132.	0.8	226
22	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. <i>Prostate</i> , 2002, 53, 109-117.	1.2	220
23	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. , 2017, 5, 22.		217
24	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
25	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3060-3069.	3.2	208
26	Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement. <i>Clinical Cancer Research</i> , 2008, 14, 3536-3544.	3.2	207
27	Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 504-514.	2.0	195
28	Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. <i>International Journal of Cancer</i> , 1983, 31, 543-552.	2.3	177
29	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. <i>Blood</i> , 2007, 110, 3192-3201.	0.6	177
30	Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. <i>Vaccine</i> , 1997, 15, 759-768.	1.7	170
31	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019, 4, .	2.3	168
32	Dual targeting of TGF- $\beta$ 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- $\beta$ 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
33	M7824, a novel bifunctional anti-PD-L1/TGF- $\beta$ 2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. <i>Oncol Immunology</i> , 2018, 7, e1426519.	2.1	162
34	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
35	Intraperitoneal Radioimmunotherapy of Ovarian Cancer with $^{177}\text{Lu}$ -CC49: A Phase I/II Study. <i>Gynecologic Oncology</i> , 1997, 65, 94-101.	0.6	161
36	Viral Vector-Based Therapeutic Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 359-371.	1.0	151

#	ARTICLE	IF	CITATIONS
37	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. <i>Clinical Cancer Research</i> , 2020, 26, 1420-1431.	3.2	151
38	The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell-Mediated Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 2471-2478.	3.2	150
39	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncoimmunology</i> , 2013, 2, e27025.	2.1	148
40	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. <i>Oncotarget</i> , 2016, 7, 86359-86373.	0.8	143
41	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4526-4531.	3.2	141
42	IL-15 superagonist/IL-15 $\beta$ Sushi-Fc fusion complex (IL-15SA/IL-15 $\beta$ Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8 $^{+}$ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. <i>Oncotarget</i> , 2016, 7, 16130-16145.	0.8	138
43	A novel bifunctional anti-PD-L1/TGF- $\beta$ 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <i>Oncoimmunology</i> , 2017, 6, e1349589.	2.1	137
44	Enhanced Functionality of CD4 $^{+}$ CD25 $^{high}$ FoxP3 $^{+}$ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1032-1040.	3.2	131
45	Multiple Costimulatory Modalities Enhance CTL Avidity. <i>Journal of Immunology</i> , 2005, 174, 5994-6004.	0.4	128
46	A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors. <i>Journal of Immunotherapy</i> , 1999, 22, 155-165.	1.2	120
47	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. <i>Journal of Immunology</i> , 2003, 170, 2523-2530.	0.4	120
48	Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy. <i>Journal of Urology</i> , 2007, 178, 1515-1520.	0.2	119
49	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015, 3, 1248-1256.	1.6	118
50	The immunocytokine NHS-IL12 as a potential cancer therapeutic. <i>Oncotarget</i> , 2014, 5, 1869-1884.	0.8	116
51	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 99-109.	3.2	116
52	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
53	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. <i>Journal of Clinical Oncology</i> , 2001, 19, 1848-1854.	0.8	113
54	Brachyury, a Driver of the Epithelial-Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3868-3879.	3.2	112

#	ARTICLE	IF	CITATIONS
55	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7164-7173.	3.2	111
56	Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant. <i>Clinical Cancer Research</i> , 2008, 14, 5284-5291.	3.2	107
57	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012, 120, 3030-3038.	0.6	107
58	ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 174, 539-546.	0.2	106
59	Strategies for Cancer Vaccine Development. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-13.	3.0	102
60	A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. <i>International Journal of Cancer</i> , 1995, 63, 231-237.	2.3	99
61	Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12. <i>Cancer Research</i> , 2009, 69, 6192-6199.	0.4	97
62	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.5	97
63	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016, 7, 37762-37772.	0.8	96
64	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1993-2005.	0.5	96
65	Acquisition of CD80 (B7-1) by T Cells. <i>Journal of Immunology</i> , 2001, 166, 2505-2513.	0.4	95
66	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
67	Generation of Stable CD4+and CD8+T Cell Lines from Patients Immunized withrasOncogene-Derived Peptides Reflecting Codon 12 Mutations. <i>Cellular Immunology</i> , 1997, 182, 137-151.	1.4	88
68	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	2.0	86
69	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. <i>Clinical Cancer Research</i> , 2006, 12, 1897-1905.	3.2	85
70	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. <i>Oncotarget</i> , 2016, 7, 33498-33511.	0.8	85
71	Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. <i>Cancer Research</i> , 2002, 62, 6944-51.	0.4	85
72	Acquisition of CD80 by Human T Cells at Early Stages of Activation: Functional Involvement of CD80 Acquisition in T Cell to T Cell Interaction. <i>Journal of Immunology</i> , 2002, 169, 6162-6169.	0.4	83

#	ARTICLE	IF	CITATIONS
73	Vaccine therapy of established tumors in the absence of autoimmunity. <i>Clinical Cancer Research</i> , 2003, 9, 1837-49.	3.2	83
74	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
75	Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice. <i>Cancer Research</i> , 2004, 64, 3668-3678.	0.4	80
76	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	3.4	80
77	The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor) Tj ETQq1 1,0,784314,rgBT /Ove	3.2	79
78	Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses. <i>Clinical Cancer Research</i> , 2005, 11, 2416-2426.	3.2	79
79	Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12. <i>Journal of Immunotherapy</i> , 2010, 33, 697-705.	1.2	79
80	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
81	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. , 2020, 8, e000450.		79
82	Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. <i>Cancer Research</i> , 2002, 62, 5770-7.	0.4	79
83	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
84	Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). <i>International Journal of Cancer</i> , 1986, 38, 661-669.	2.3	76
85	Vaccination with a Recombinant <i>Saccharomyces cerevisiae</i> Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses. <i>Clinical Cancer Research</i> , 2008, 14, 4316-4325.	3.2	76
86	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. <i>Cancer Immunology Research</i> , 2016, 4, 452-462.	1.6	76
87	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. , 2019, 7, 82.		76
88	SDR grafting—a new approach to antibody humanization. <i>Methods</i> , 2005, 36, 25-34.	1.9	75
89	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
90	A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). <i>International Journal of Cancer</i> , 1991, 48, 900-907.	2.3	73

#	ARTICLE	IF	CITATIONS
91	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 517-529.	2.0	73
92	Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only. <i>Journal of Immunology</i> , 2000, 164, 1432-1441.	0.4	71
93	Generation, Characterization, and in Vivo Studies of Humanized Anticarcinoma Antibody CC49. <i>Hybridoma</i> , 1995, 14, 461-473.	0.9	68
94	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
95	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. <i>Oncotarget</i> , 2017, 8, 8807-8817.	0.8	68
96	Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. , 2000, 85, 829-838.		66
97	&lt;p&gt;Therapeutic Vaccines for HPV-Associated Malignancies&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 167-200.	2.7	66
98	Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. <i>Clinical Cancer Research</i> , 2002, 8, 41-53.	3.2	66
99	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	65
100	Ca 72-4 radioimmunoassay for the detection of the tag-72 carcinoma-associated antigen in serum of patients. <i>Journal of Clinical Laboratory Analysis</i> , 1989, 3, 360-369.	0.9	64
101	SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. <i>Molecular Immunology</i> , 2004, 41, 863-872.	1.0	64
102	The Use of Chelated Radionuclide (Samarium-153-Ethylendiaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing. <i>Clinical Cancer Research</i> , 2008, 14, 4241-4249.	3.2	64
103	Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. <i>Oncotarget</i> , 2013, 4, 1777-1790.	0.8	63
104	Anti-Tumor Immunity Elicited by a Recombinant Vaccinia Virus Expressing CD70 (CD27L). <i>Human Gene Therapy</i> , 1999, 10, 1095-1103.	1.4	62
105	A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1. <i>Clinical Cancer Research</i> , 2004, 10, 2139-2149.	3.2	60
106	Recombinant <i>Saccharomyces cerevisiae</i> (yeast-CEA) as a potent activator of murine dendritic cells. <i>Vaccine</i> , 2008, 26, 509-521.	1.7	60
107	Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1985, 5, 269-276.	1.1	59
108	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. <i>Journal of Immunology</i> , 2013, 190, 6250-6258.	0.4	59



#	ARTICLE	IF	CITATIONS
109	A radioimmunoassay for the detection of a human tumor-associated glycoprotein (tag-72) using monoclonal antibody B72.3. <i>International Journal of Cancer</i> , 1986, 37, 659-666.	2.3	56
110	Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. <i>European Journal of Immunology</i> , 1996, 26, 435-443.	1.6	56
111	Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin. <i>Clinical Cancer Research</i> , 2005, 11, 6342-6351.	3.2	56
112	An IL-15 superagonist/IL-15R $\alpha$ fusion complex protects and rescues NK cell-cytotoxic function from TGF- $\beta$ 1-mediated immunosuppression. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 675-689.	2.0	55
113	Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. <i>Cancer Research</i> , 2003, 63, 7942-9.	0.4	55
114	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1259-1270.	0.4	54
115	Simultaneous inhibition of CXCR1/2, TGF- $\beta$ 2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
116	TRICOM Vector Based Cancer Vaccines. <i>Current Pharmaceutical Design</i> , 2006, 12, 351-361.	0.9	53
117	Chitosan solution enhances the immunoadjuvant properties of GM-CSF. <i>Vaccine</i> , 2007, 25, 8673-8686.	1.7	53
118	A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2010, 16, 4046-4056.	3.2	53
119	Dual inhibition of TGF- $\beta$ 2 and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
120	Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation. , 1997, 72, 949-954.		52
121	A fully human IgG1 anti-PD-L1 MAb in an <i>in vitro</i> assay enhances antigen-specific T cell responses. <i>Clinical and Translational Immunology</i> , 2016, 5, e83.	1.7	52
122	TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. <i>Cancer</i> , 1993, 72, 2098-2106.	2.0	51
123	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 197-206.	2.0	51
124	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>OncImmunology</i> , 2018, 7, e1466018.	2.1	51
125	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017, 23, 6833-6845.	3.2	51
126	Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. <i>International Journal of Cancer</i> , 1987, 40, 726-733.	2.3	50



#	ARTICLE	IF	CITATIONS
127	Phase I Study of Recombinant CEA Vaccinia Virus Vaccine with Post Vaccination CEA Peptide Challenge. Medical University of South Carolina, Charleston, South Carolina. Human Gene Therapy, 1996, 7, 1381-1394.	1.4	50
128	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. Clinical Cancer Research, 2013, 19, 1290-1299.	3.2	50
129	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. Journal of Circulating Biomarkers, 2016, 5, 5.	0.8	50
130	Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. , 2020, 8, e000612.		50
131	Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF- $\beta$ 2 signaling enables PD-L1-mediated tumor eradication. Journal of Clinical Investigation, 2022, 132, .	3.9	50
132	Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. International Journal of Cancer, 1986, 38, 643-650.	2.3	49
133	PART V. Modulation of Antitumor Vaccine StrategiesPreclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. Critical Reviews in Immunology, 2007, 27, 451-462.	1.0	49
134	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget, 2017, 8, 20558-20571.	0.8	49
135	Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. Journal of Immunological Methods, 2002, 268, 197-210.	0.6	48
136	Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	48
137	Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. Cancer, 1984, 54, 2777-2794.	2.0	47
138	Construction and Characterization of a Recombinant Vaccinia Virus Expressing Murine Intercellular Adhesion Molecule-1: Induction and Potentiation of Antitumor Responses. Human Gene Therapy, 1997, 8, 851-860.	1.4	46
139	Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 705-709.	1.4	46
140	Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. International Journal of Cancer, 1989, 44, 208-218.	2.3	45
141	Biologic properties of a Ch2 domain-deleted recombinant immunoglobulin. International Journal of Cancer, 1993, 53, 97-103.	2.3	45
142	CA 72-4 Serum Marker-“A New Tool in the Management of Carcinoma Patients. Cancer Investigation, 1995, 13, 227-238.	0.6	45
143	Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL. Journal of Immunology, 2005, 175, 3715-3723.	0.4	45
144	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clinical Cancer Research, 2019, 25, 4933-4944.	3.2	45

#	ARTICLE	IF	CITATIONS
145	Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2005, 11, 1597-1607.	3.2	44
146	Overcoming hypoxia-induced functional suppression of NK cells. , 2020, 8, e000246.		44
147	Analyses of functions of an anti-PD-L1/TGF $\beta$ 2R2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
148	Grafting of $\alpha$ Abbreviated $\beta$ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody. <i>Journal of Immunology</i> , 2002, 169, 3076-3084.	0.4	43
149	Paradigm Shifts in Cancer Vaccine Therapy. <i>Experimental Biology and Medicine</i> , 2008, 233, 522-534.	1.1	43
150	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
151	mRNA Expression of Transforming Growth Factor Alpha in Human Breast Carcinomas and Its Activity in Effusions of Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1989, 81, 1165-1171.	3.0	42
152	Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. <i>European Journal of Immunology</i> , 1995, 25, 2588-2597.	1.6	41
153	Physiological relevance of antigen presentosome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs. <i>Blood</i> , 2005, 105, 3238-3246.	0.6	41
154	Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1173-1183.	2.0	41
155	Effect of a small molecule BCL $\beta$ inhibitor on immune function and use with a recombinant vaccine. <i>International Journal of Cancer</i> , 2010, 127, 1603-1613.	2.3	41
156	Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	41
157	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
158	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
159	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. <i>Nature Communications</i> , 2021, 12, 5151.	5.8	41
160	Minimizing the Immunogenicity of Antibodies for Clinical Application. <i>Tumor Biology</i> , 2005, 26, 31-43.	0.8	40
161	Anti-PD-L1/TGF $\beta$ 2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 93.e1-93.e11.	0.8	40
162	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. <i>JCI Insight</i> , 2019, 4, .	2.3	40

#	ARTICLE	IF	CITATIONS
163	Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: Comparison of in vivo gamma probe counts within vitro MAb radiolocalization. <i>International Journal of Cancer</i> , 1988, 42, 352-358.	2.3	39
164	Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2004, 10, 1090-1099.	3.2	39
165	Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 397-408.	2.0	39
166	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 479-e899.	1.9	39
167	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1521-1531.	2.0	38
168	Samarium-153-EDTMP (Quadramet <sup>®</sup> ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016, 7, 69014-69023.	0.8	38
169	Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 27-39.	1.1	37
170	Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells. <i>Clinical Cancer Research</i> , 2005, 11, 5603-5615.	3.2	37
171	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. <i>International Journal of Cancer</i> , 2017, 141, 583-593.	2.3	37
172	Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. <i>Cancer</i> , 1991, 68, 2443-2450.	2.0	36
173	Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. <i>Vaccine</i> , 2001, 19, 3552-3567.	1.7	36
174	Definition of the expression of the human carcinoembryonic antigen and non- $\alpha$ -specific cross-reacting antigen in human breast and lung carcinomas. <i>International Journal of Cancer</i> , 1993, 53, 892-897.	2.3	36
175	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
176	Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. <i>Cancer</i> , 1994, 73, 993-998.	2.0	35
177	Amplification of the lytic potential of effector/memory CD8 <sup>+</sup> cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. <i>Cancer Gene Therapy</i> , 2004, 11, 665-680.	2.2	35
178	4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. <i>Vaccine</i> , 2006, 24, 4975-4986.	1.7	35
179	The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1471-1484.	2.0	35
180	Translational Research Working Group Developmental Pathway for Immune Response Modifiers. <i>Clinical Cancer Research</i> , 2008, 14, 5692-5699.	3.2	35

#	ARTICLE	IF	CITATIONS
181	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
182	Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Research, 2002, 62, 5058-64.	0.4	35
183	The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Anticancer Research, 2020, 40, 5329-5341.	0.5	34
184	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. , 2021, 9, e001691.		34
185	Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood, 2005, 106, 3515-3523.	0.6	32
186	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opinion on Biological Therapy, 2010, 10, 19-28.	1.4	32
187	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget, 2015, 6, 31344-31359.	0.8	32
188	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. ELife, 2020, 9, .	2.8	32
189	Identification of a Human CD8+T Lymphocyte Neo-epitope Created by arasCodon 12 Mutation Which Is Restricted by the HLA-A2 Allele. Cellular Immunology, 1998, 187, 103-116.	1.4	31
190	Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Experimental Biology and Medicine, 2011, 236, 537-545.	1.1	31
191	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. International Journal of Cancer, 2013, 133, 373-382.	2.3	31
192	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process. Cancer Research, 2014, 74, 1945-1957.	0.4	31
193	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN- $\gamma$ -2b in patients with CEA-expressing carcinomas. Cancer Immunology, Immunotherapy, 2016, 65, 1353-1364.	2.0	31
194	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. Oncologist, 2021, 26, e847-e858.	1.9	31
195	Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.. Journal of Clinical Oncology, 2014, 32, 3064-3064.	0.8	31
196	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. OncoImmunology, 2019, 8, e1532764.	2.1	30
197	ras oncogene p21 as a tumor marker in the cytodiagnosis of gastric and colonic carcinomas. Cancer, 1987, 60, 2432-2436.	2.0	28
198	Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-pan-2 in normal, benign and malignant pancreatic tissue. International Journal of Cancer, 1988, 42, 681-686.	2.3	28

#	ARTICLE	IF	CITATIONS
199	Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. <i>Molecular Immunology</i> , 2003, 40, 337-349.	1.0	28
200	Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells. <i>Journal of Immunology</i> , 2008, 180, 5871-5881.	0.4	28
201	Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. <i>Vaccine</i> , 2009, 27, 4475-4482.	1.7	28
202	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 63-71.	2.0	28
203	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4501-4501.	0.8	28
204	Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms. <i>Vigiliae Christianae</i> , 1987, 53, 146-152.	0.1	27
205	Immunization with a Syngeneic Tumor Infected with Recombinant Vaccinia Virus Expressing Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Induces Tumor Regression and Long-Lasting Systemic Immunity. <i>Journal of Immunotherapy</i> , 1997, 20, 449-459.	1.2	27
206	The diversity of T-cell co-stimulation in the induction of antitumor immunity. <i>Immunological Reviews</i> , 1999, 170, 73-84.	2.8	27
207	CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. <i>Molecular Immunology</i> , 1999, 36, 1079-1091.	1.0	27
208	Vaccines as an Integral Component of Cancer Immunotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2195.	3.8	27
209	Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. , 2020, 8, e000493.		27
210	Enhanced Immune Responses and Anti-Tumor Activity by Baculovirus Recombinant Carcinoembryonic Antigen (CEA) in Mice Primed with the Recombinant Vaccinia CEA. <i>Journal of Immunotherapy</i> , 1994, 16, 275.	1.2	26
211	Induction of Anti-Tumor Immunity Elicited by Tumor Cells Expressing a Murine LFA-3 Analog via a Recombinant Vaccinia Virus. <i>Human Gene Therapy</i> , 1999, 10, 623-631.	1.4	26
212	TGF- $\beta$ 2 modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1809-1818.	2.0	26
213	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. <i>OncImmunology</i> , 2016, 5, e1188243.	2.1	26
214	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 704-716.	3.2	26
215	Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions. <i>Breast Cancer Research and Treatment</i> , 1985, 6, 49-56.	1.1	25
216	Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclox), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. <i>Journal of Immunology</i> , 2014, 192, 2622-2633.	0.4	25

#	ARTICLE	IF	CITATIONS
217	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
218	Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1247-1258.	2.0	24
219	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1409-1418.	1.4	24
220	The role of soluble CD40L in immunosuppression. <i>OncolImmunology</i> , 2013, 2, e22546.	2.1	24
221	Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. <i>Oncotarget</i> , 2015, 6, 4853-4862.	0.8	24
222	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 161-174.	2.0	23
223	Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1307-1317.	2.0	23
224	NHS-IL12, a Tumor-Targeting Immunocytokine. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 155-169.	2.7	23
225	Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. <i>Current Opinion in Immunology</i> , 2000, 12, 85-91.	2.4	22
226	Maturation of human dendritic cells with <i>Saccharomyces cerevisiae</i> (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. <i>Vaccine</i> , 2011, 29, 4992-4999.	1.7	22
227	Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1359-1370.	1.6	22
228	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. <i>Oral Oncology</i> , 2019, 90, 38-44.	0.8	22
229	Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ 2, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3006-3006.	0.8	21
230	Applications of Immunocytochemistry to Clinical Cytology. <i>Cancer Investigation</i> , 1987, 5, 593-611.	0.6	20
231	Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. , 2019, 7, 150.		20
232	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. , 2021, 9, e002128.		20
233	In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. <i>Clinical Cancer Research</i> , 2003, 9, 5521-31.	3.2	20
234	In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 471-480.	3.3	19



#	ARTICLE	IF	CITATIONS
235	Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. <i>Cancer Detection and Prevention</i> , 2002, 26, 275-291.	2.1	19
236	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). <i>International Journal of Cancer</i> , 2007, 121, 595-605.	2.3	19
237	The Use of a Humanized NSG- $\hat{I}^2m^{\hat{a}}/\hat{a}^{\hat{a}}$ Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa. <i>Frontiers in Oncology</i> , 2020, 10, 549.	1.3	19
238	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
239	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3055-3055.	0.8	19
240	Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. <i>Oncotarget</i> , 2017, 8, 90825-90841.	0.8	18
241	ABO blood type correlates with survival on prostate cancer vaccine therapy. <i>Oncotarget</i> , 2015, 6, 32244-32256.	0.8	18
242	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
243	Potential for recombinant immunoglobulin constructs in the management of carcinoma. <i>Cancer</i> , 1994, 73, 1105-1113.	2.0	17
244	Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1897-1910.	2.0	17
245	Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 955-965.	2.0	17
246	Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. <i>Vaccine</i> , 2017, 35, 2605-2611.	1.7	17
247	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. <i>Journal of Neurosurgery</i> , 2018, 128, 1419-1427.	0.9	17
248	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020, 25, 560.	1.9	17
249	Persistence, Immune Specificity, and Functional Ability of Murine Mutant Ras Epitope-Specific CD4+ and CD8+ T Lymphocytes Following in Vivo Adoptive Transfer. <i>Cellular Immunology</i> , 1999, 194, 78-89.	1.4	16
250	Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis. <i>Blood</i> , 2007, 109, 2488-2495.	0.6	16
251	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018, 4, 636-638.	1.6	16
252	Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation. <i>Journal of Immunology</i> , 2012, 188, 4323-4333.	0.4	15



#	ARTICLE	IF	CITATIONS
253	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 122.	1.8	15
254	Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. <i>Cytokine</i> , 2003, 24, 128-142.	1.4	14
255	IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	14
256	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	1.5	14
257	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2501-2501.	0.8	14
258	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2013, 31, 102-102.	0.8	14
259	Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic amp analogue: A comparison with interferon-gamma. <i>International Journal of Cancer</i> , 1991, 48, 413-422.	2.3	13
260	Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 43-57.	2.0	13
261	General Keynote: Vaccine Strategies for the Therapy of Ovarian Cancer. <i>Gynecologic Oncology</i> , 2003, 88, S97-S104.	0.6	13
262	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. , 2020, 8, e001019.		13
263	Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies. , 2019, , .		13
264	Generation, purification, and characterization of a recombinant source of human prostate-specific antigen. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 261-268.	0.9	12
265	Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. <i>Expert Review of Vaccines</i> , 2003, 2, 483-493.	2.0	12
266	Combination therapies utilizing neoepitope-targeted vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 875-885.	2.0	12
267	Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009. <i>JCI Insight</i> , 2021, 6, .	2.3	12
268	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
269	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 735-740.	2.0	12
270	Recent Advances in Therapeutic Cancer Vaccines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 2-5.	0.7	11

#	ARTICLE	IF	CITATIONS
271	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581801.	1.3	11
272	Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. , 2021, 9, e002258.		11
273	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. <i>Cancer Immunology Research</i> , 2021, 9, 239-252.	1.6	11
274	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2526-2526.	0.8	11
275	Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. <i>International Journal of Cancer</i> , 1990, 46, 1021-1028.	2.3	10
276	Phase I Trial of an Enhanced Prostate-Specific Antigen-Based Vaccine and Anti-CTLA-4 Antibody in Patients with Metastatic Androgen-Independent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 347-350.	0.9	10
277	Immunology of Lynch Syndrome. <i>Current Oncology Reports</i> , 2021, 23, 96.	1.8	10
278	Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. <i>Clinical and Translational Science</i> , 2010, 3, 116-122.	1.5	9
279	Effect of Talactoferrin Alfa on the Immune System in Adults With Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 821-822.	1.9	9
280	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. <i>Cancers</i> , 2021, 13, 968.	1.7	9
281	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
282	Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein. <i>Oncotarget</i> , 2017, 8, 73469-73482.	0.8	9
283	Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. <i>Clinical Cancer Research</i> , 2003, 9, 1616-27.	3.2	9
284	Development of quantitative liquid competition radioimmunoassays for theras oncogene and proto-oncogene p21 products. <i>International Journal of Cancer</i> , 1986, 38, 587-595.	2.3	8
285	Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas. <i>Journal of Surgical Oncology</i> , 1991, 48, 9-13.	0.8	8
286	Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. <i>Journal of Surgical Oncology</i> , 1991, 48, 16-20.	0.8	8
287	Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. <i>International Journal of Cancer</i> , 2000, 85, 508-517.	2.3	8
288	The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-8.	3.0	8

#	ARTICLE	IF	CITATIONS
289	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11527-11527.	0.8	8
290	Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. , 2022, 10, e004601.		8
291	Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 503-515.	2.0	7
292	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
293	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
294	Abstract 594: Dual targeting of TGF $\beta$ and PD-L1 promotes potent anti-tumor efficacy in multiple murine models of solid carcinomas. <i>Cancer Research</i> , 2017, 77, 594-594.	0.4	7
295	Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20106-e20106.	0.8	7
296	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF $\beta$ 2RII agent: Current status. <i>Experimental Biology and Medicine</i> , 2022, 247, 1124-1134.	1.1	7
297	Assay for the detection of anti-idiotypic antibodies to monoclonal antibody b72.3. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 465-473.	0.9	6
298	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3081-3081.	0.8	6
299	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4590-TPS4590.	0.8	6
300	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. <i>Journal of Immunological Methods</i> , 2003, 279, 183-192.	0.6	5
301	Potential utility of the pan-Bcl-2 inhibitor GX15 $\hat{a}$ 070 (obatoclox) in cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e29351.	2.1	5
302	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , 2014, 135, 862-870.	2.3	5
303	Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. <i>Oncolmmunology</i> , 2021, 10, 1915561.	2.1	5
304	Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5081-TPS5081.	0.8	5
305	Immunotherapy for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 215-215.	0.8	5
306	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. <i>JCI Insight</i> , 2022, 7, .	2.3	5

#	ARTICLE	IF	CITATIONS
307	Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab <sup>2</sup> . <i>Proteins: Structure, Function and Bioinformatics</i> , 1993, 17, 438-443.	1.5	4
308	Monoclonal Antibody Gene Transfer: Implications for Tumor-Specific Cell-Mediated Cytotoxicity. <i>Annals of the New York Academy of Sciences</i> , 1994, 716, 154-166.	1.8	4
309	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. <i>Cancers</i> , 2012, 4, 1333-1348.	1.7	4
310	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. <i>Npj Vaccines</i> , 2021, 6, 86.	2.9	4
311	Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2518-2518.	0.8	4
312	The MUC1-C oncoprotein as a target in hematologic malignancies. <i>Cancer Biology and Therapy</i> , 2010, 10, 492-494.	1.5	3
313	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I). <i>Journal of Clinical Oncology</i> , 2021, 39, 4599-4606.	1.0	3
314	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4599-TPS4599.	0.8	3
315	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5096-TPS5096.	0.8	3
316	Abstract 1480: Systemic immunotherapeutic efficacy of an immunocytokine, NHS-muIL12, in a superficial murine orthotopic bladder cancer model. <i>Cancer Research</i> , 2016, 76, 1480-1480.	0.4	3
317	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 93-93.	0.8	3
318	Cancer vaccine development. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1439-1452.	1.9	2
319	Recombinant cancer vaccines and new vaccine targets. <i>Expert Review of Vaccines</i> , 2013, 12, 1121-1124.	2.0	2
320	Insights on Peptide Vaccines in Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, 1, 1-27.	0.2	2
321	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1429-1435.	2.0	2
322	The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 1435-1438.	1.9	2
323	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	0.8	2
324	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14026-e14026.	0.8	2

#	ARTICLE	IF	CITATIONS
325	Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.. Journal of Clinical Oncology, 2015, 33, 3038-3038.	0.8	2
326	Monoclonal antibodies in the management of carcinoma patients. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 223-228.	1.0	2
327	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. Journal of Clinical Oncology, 2015, 33, e14008-e14008.	0.8	2
328	OUP accepted manuscript. Oncologist, 2022, 27, e353-e356.	1.9	2
329	The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase I study.. Journal of Clinical Oncology, 2022, 40, 127-127.	0.8	2
330	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 130-130.	0.8	2
331	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
332	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1
333	The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro.. Journal of Clinical Oncology, 2015, 33, e14012-e14012.	0.8	1
334	Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 597-597.	0.8	1
335	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. Journal of Cancer Prevention, 2021, 26, 309-317.	0.8	1
336	Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.. Journal of Clinical Oncology, 2022, 40, e17033-e17033.	0.8	1
337	176 Vector-based Vaccines for Cancer Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	0.9	0
338	Introduction: Therapeutic Cancer Vaccines. Seminars in Oncology, 2012, 39, 243-244.	0.8	0
339	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors. , 2014, , 315-334.		0
340	EXTH-63. EFFICIENT ADCC-MEDIATED KILLING OF MALIGNANT MENINGIOMA CELLS USING AVELUMAB AND AN ENGINEERED HIGH AVIDITY NATURAL KILLER CELL LINE, haNK. Neuro-Oncology, 2018, 20, vi98-vi98.	0.6	0
341	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. Journal of Clinical Oncology, 2021, 39, 2617-2617.	0.8	0
342	Pox Viral Vaccines. , 2004, , 175-191.		0

#	ARTICLE	IF	CITATIONS
343	Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL.. Blood, 2004, 104, 2516-2516.	0.6	0
344	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. , 2010, , 305-319.		0
345	Safety profile of poxviral vaccines: NCI experience.. Journal of Clinical Oncology, 2013, 31, 85-85.	0.8	0
346	Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.. Journal of Clinical Oncology, 2018, 36, 5021-5021.	0.8	0
347	Recombinant Viral and Bacterial Vaccines. , 2007, , 217-250.		0
348	Combination Therapies for HPV-Associated Malignancies. Journal of Clinical & Cellular Immunology, 2021, 12, .	1.5	0
349	Peptide-based vaccines. , 2022, , 155-173.		0
350	Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.. Journal of Clinical Oncology, 2022, 40, 249-249.	0.8	0